Einsatz von mTOR-Inhibitoren bei soliden Tumoren
Standard
Einsatz von mTOR-Inhibitoren bei soliden Tumoren. / Seidel, Christoph; Grünwald, Viktor.
in: Med Monatsschr Pharm, Jahrgang 34, Nr. 4, 04.2011, S. 116-26; quiz 127-8.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Einsatz von mTOR-Inhibitoren bei soliden Tumoren
AU - Seidel, Christoph
AU - Grünwald, Viktor
PY - 2011/4
Y1 - 2011/4
N2 - mTOR-inhibitors are part of targeted agents and are already in use in the clinic, especially for treatment of metastatic renal cell carcinoma. Distinct from conventional chemotherapeutics, targeted agents imply chronic treatment, which has changed our perspective on the commerce of adverse events (AE). In principle, mTOR-inhibitors are associated with a broad number of AEs. The occurrence of stomatitis, infection, pneumonitis, hyperlipidemia and hyperglycemia are considered major class effects of mTOR-inhibitors. However, severe adverse events remain scarce among mTOR-inhibitors and support chronic use of these agents. Based on their good clinical tolerability mTOR-inhibitors are prone to be developed in combinational therapies. However, the hepatic metabolism of these agents may limit their use to partners with a distinct metabolism in order to avoid drug interaction. Meanwhile about 40 different trials use mTOR-inhibitors in different tumor entities. The use of mTOR-inhibitors in neuroendocine tumors of the intestine, mantle cell lymphoma and sarcomas has hereby shown to be very promising. The mainstay of therapy already incorporates the use of everolimus in second line and temsirolimus in first line treatment in patients with metastatic renal cell carcinoma.
AB - mTOR-inhibitors are part of targeted agents and are already in use in the clinic, especially for treatment of metastatic renal cell carcinoma. Distinct from conventional chemotherapeutics, targeted agents imply chronic treatment, which has changed our perspective on the commerce of adverse events (AE). In principle, mTOR-inhibitors are associated with a broad number of AEs. The occurrence of stomatitis, infection, pneumonitis, hyperlipidemia and hyperglycemia are considered major class effects of mTOR-inhibitors. However, severe adverse events remain scarce among mTOR-inhibitors and support chronic use of these agents. Based on their good clinical tolerability mTOR-inhibitors are prone to be developed in combinational therapies. However, the hepatic metabolism of these agents may limit their use to partners with a distinct metabolism in order to avoid drug interaction. Meanwhile about 40 different trials use mTOR-inhibitors in different tumor entities. The use of mTOR-inhibitors in neuroendocine tumors of the intestine, mantle cell lymphoma and sarcomas has hereby shown to be very promising. The mainstay of therapy already incorporates the use of everolimus in second line and temsirolimus in first line treatment in patients with metastatic renal cell carcinoma.
KW - Animals
KW - Antineoplastic Agents
KW - Carcinoma, Renal Cell
KW - Drug Interactions
KW - Drug Therapy, Combination
KW - Humans
KW - Immunosuppressive Agents
KW - Kidney Neoplasms
KW - Neoplasm Metastasis
KW - Neoplasms
KW - Sirolimus
KW - TOR Serine-Threonine Kinases
M3 - SCORING: Zeitschriftenaufsatz
C2 - 21528529
VL - 34
SP - 116-26; quiz 127-8
JO - Med Monatsschr Pharm
JF - Med Monatsschr Pharm
SN - 0342-9601
IS - 4
ER -